Translational Research > Gynaecological Cancer > Dr John Green

Professional Memberships 

• American Society for Clinical Oncology (Member)
• Association of Cancer Physicians (Member)
• British Gynaecological Cancer Society (Secretary)
• Gynecological Cancer Intergroup (Member)
• National Cancer Research Institute Clinical Studies Group (Sub-committee member)
• American Association of Cancer Research (Member)
• European Society for Gynaecological Oncology (Member)
• International Gynecological Cancer Society (Member)

• DeCruze B, Green JA (2007) A systematic review of hormone therapy in advanced endometrial cancer. International Journal of Gynecological Cancer,17(5),pp.964-78
 
• Athavale R, Clooney K, Clark AC, OHagan JO and Green JA (2006) Optimizing Treatment for Cervical Cancer. International Journal of Gynecological Cancer,16(),pp.215-227 

• Green JA, Berns E, van der Burg M and 8 others (2006) Alterations in the p53 pathway adn prognosis in advanced ovarian cancer: a multifactorial analysis of teh EORTC Gynaaecological Cancer Group. European Journal of Cancer,42(15),pp.2539-48
 
• Humber CS, Tierney J, Symonds PS, Kirwan J, Williams CJ, Green JA (2005) Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Cochrane Library,(5),pp.409-420 

• Symonds RP, Collingwood M, Kirwan J, Humber CE, Tierney JF, Green JA and Williams C. (2004) Cytotoxic chemotherapy for advanced or recurrent cervical cancer. Cancer Treatment Reviews,(),pp.230-232 

• Kirwan JM, Symonds P, GREEN JA, Tierney J, Collingwood M,and Williams CJ (2003) A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiotherapy and Oncology ,(),pp.217-226 

• Green JA (2003) Early ovarian cancer - time for a rethink on stage?. Gynecological Oncology,90(),pp.2539-2548 

• Green J A, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams CJ. (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The Lancet,358(),pp.781-786 

• Adams G, Wong H, Walking J,Green JA (2010) Single agent carboplatin or combination chemotherapy for early stage ovarian cancer. British Journal of Obstetrics and Gynaecology,117(12)(),pp.1459-67 

• Fleeman N, Bagust A, McLeod C, Greenhalgh J, Dundar Y, Boland A, Dundar Y, Dickson R, Tudor Smith, Davis H, Green J, Pearson M (2010) pemetrexed for the first line management of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment ,14(1),pp.47-54 

• Greenhalgh, J., C. McLeod, A. Bagust, Boland, N. Fleeman, Y. Dundar, J. Oyee, R. Dickson, H. Davis, J. Green, et al (2010) Pemetrexed for maintenance treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC):A Single Technology Appraisal. Health Technology Assessment,14(Supp 2),pp.33-39 

• Lim SL, Syed N, Smith P, Coens C, van der Burg MEL, Green JA (2008) Promoter methylation of FancF in advanced epithelial carcinoma. British Journal of Cancer ,98((8)),pp.1452-1456 

• Green JA,Dundar Y, Haycox A, Bagust A, Hill R, Dickson R, Mcleod C, Dodd S, Walley T and Green JA (2007) Pemetrexed disodium in the treatment of malignant mesothelioma: systematic review. Cochrane Review,11(1),pp. 

• DeCruze B, Green JA (2007) A systematic review of hormone therapy in advanced endometrial cancer. International Journal of Gynecological Cancer,17(5),pp.964-78 

• Lim S, van der Burg M, Crook T, Green JA (2007) DUSP 7 and 8 as prognostic factors in advanced ovarian cancer. Proceedings ASCO,24(),pp. 

• Humber C, Tierney J T, Symonds P, Collingwood M, Kirwan J, Williams C, Green JA (2007) A systematic review and meta-analysis of cytotoxic chemotherapy in advanced endometrial cancer. Annals of Oncology,18(3),pp.409-420 

• Dundar Y, Boland A, Dickson R, Green JA, Walley T (2007) Pemetrexed disodium in the treatment of malignant mesothelioma. Health Technology Assessment,11(1)(),pp.1-80 

• Athavale R, Clooney K, Clark AC, OHagan JO and Green JA (2006) Optimizing Treatment for Cervical Cancer. International Journal of Gynecological Cancer,16(),pp.215-227 

• Green JA, Berns E, van der Burg M and 8 others (2006) Alterations in the p53 pathway adn prognosis in advanced ovarian cancer: a multifactorial analysis of teh EORTC Gynaaecological Cancer Group. European Journal of Cancer,42(15),pp.2539-48
 
• Macdonald R, Kirwan J, Roberts S, Gray D, Allsopp L, Green J (2006) A questionnaire based assessment of the management of ascites in ovarian cancer. Journal of Palliative Medicine,9(6)(),pp.1264-1270 

• Green JA, Lainakis G (2006) Systemic chemotherapy for advanced or recurrent cervical cancer. Annals of Oncology,17(10),pp.230-232